• Explore /
  • Poster
  • / Safety and efficacy of IBI343 (anti-claudin18.2 antibody-drug conjugate) in patients with advanced pancreatic ductal adenocarcinoma or biliary tract cancer: Preliminary results from a phase 1 study.

Safety and efficacy of IBI343 (anti-claudin18.2 antibody-drug conjugate) in patients with advanced pancreatic ductal adenocarcinoma or biliary tract cancer: Preliminary results from a phase 1 study.

Abstract Poster

Authors

null

Xianjun Yu

Fudan University Shanghai Cancer Center, Shanghai, China

Xianjun Yu , Jian Zhang , Andrea Tazbirkova , Jianwei Yang , Jinbo Yue , Yuping Sun , Yueyin Pan , Meili Sun , Yanru Qin , Lin Shen , Rongfeng Song , Jian Ruan , Aiping Zhou , Yiping Mou , Zimin Liu , Zhenyang Liu , Yongchang Zhang , Michelle Morris , Morteza Aghmesheh , Hui Zhou

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2024 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

Track

Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

Sub Track

Chemotherapy and Antibody-Drug Conjugates

Clinical Trial Registration Number

NCT05458219

Citation

J Clin Oncol 42, 2024 (suppl 16; abstr 3037)

DOI

10.1200/JCO.2024.42.16_suppl.3037

Abstract #

3037

Poster Bd #

182

Abstract Disclosures

Similar Posters

First Author: Panpan Zhang

First Author: Xinan Sheng

First Author: Shuiling Jin

First Author: Jun Zhou